Skip to main content
Livermore
Livermore
ZHEN

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q4 2023

Holdings as of Dec 31, 2023, filed Feb 13, 2024. Long positions only; changes compare share counts with Q3 2023.

Institution overview
Positions
73
+4 vs. Q3 2023
Portfolio value
$501.5M
+$195.5M (+63.9%) vs. Q3 2023
Filed
Feb 13, 2024
SEC
Holdings of Affinity Asset Advisors, LLC in Q4 2023
SecurityClassSharesValue% of portfolioShare changeActionHistory
Rocket Pharmaceuticals, Inc.77313F114*W EXP 09/02/20275,000$36.8K<0.1%00.0%Unchanged–
ARAVAravive, Inc.COM346,511$42.9K<0.1%00.0%UnchangedHistory
PMNProMIS Neurosciences Inc.COM265,958$305.9K0.1%00.0%UnchangedHistory
IFRXInflaRx N.V.COM200,097$326.2K0.1%−125,000−38.5%ReducedHistory
CNTXContext Therapeutics Inc.COM328,817$371.6K0.1%00.0%UnchangedHistory
NUVBNuvation Bio Inc.COM CL A250,000$377.5K0.1%00.0%UnchangedHistory
TERNTerns Pharmaceuticals, Inc.COM66,000$428.3K0.1%−259,000−79.7%ReducedHistory
NAMSWNewAmsterdam Pharma Co N.V.*W EXP 11/22/202137,000$428.8K0.1%00.0%UnchangedHistory
Immatics N.V.N44445117*W EXP 07/01/202187,204$546.6K0.1%00.0%Unchanged–
TECXTectonic Therapeutic, Inc.COM500,000$680.0K0.1%00.0%UnchangedHistory
FULCFulcrum Therapeutics, Inc.COM125,000$843.8K0.2%+125,000NewHistory
PBYIPuma Biotechnology, Inc.COM202,349$876.2K0.2%00.0%UnchangedHistory
BHVNBiohaven Ltd.COM20,866$893.1K0.2%−9,290−30.8%ReducedHistory
VRDNViridian Therapeutics, Inc.COM50,000$1.09M0.2%+50,000NewHistory
MORFMorphic Holding, Inc.COM42,670$1.23M0.2%−227,330−84.2%ReducedHistory
ALLOAllogene Therapeutics, Inc.COM400,000$1.28M0.3%+400,000NewHistory
NARIInari Medical, Inc.Stock20,000$1.30M0.3%+20,000NewHistory
NBIXNeurocrine Biosciences IncStock10,000$1.32M0.3%+10,000NewHistory
NAMSNewAmsterdam Pharma Co N.V.ORDINARY SHARES125,000$1.40M0.3%00.0%UnchangedHistory
MIRMMirum Pharmaceuticals, Inc.COM50,000$1.48M0.3%+20,000+66.7%AddedHistory
KALVKalVista Pharmaceuticals, Inc.COM125,969$1.54M0.3%−152,323−54.7%ReducedHistory
PCVXVaxcyte, Inc.COM25,000$1.57M0.3%00.0%UnchangedHistory
ADCTADC Therapeutics SASHS1,013,540$1.68M0.3%−86,460−7.9%ReducedHistory
TRMLTourmaline Bio, Inc.COM68,081$1.78M0.4%+68,081NewHistory
PENPenumbra IncCOM7,500$1.89M0.4%+7,500NewHistory
IMTXImmatics N.V.SHS200,000$2.11M0.4%00.0%UnchangedHistory
MRSNMersana Therapeutics, Inc.COM1,000,000$2.32M0.5%−1,850,000−64.9%ReducedHistory
ASNDAscendis Pharma A/SSPONSORED ADR20,000$2.52M0.5%−26,400−56.9%ReducedHistory
EYPTEyePoint, Inc.COM NEW109,900$2.54M0.5%+109,900NewHistory
KURAKura Oncology, Inc.COM191,535$2.75M0.5%−665,000−77.6%ReducedHistory
ARGXArgenx SESPONSORED ADR7,500$2.85M0.6%+7,500NewHistory
TNGXTango Therapeutics, Inc.COM300,274$2.97M0.6%−49,726−14.2%ReducedHistory
CGEMCullinan Therapeutics, Inc.COM300,000$3.06M0.6%+300,000NewHistory
KRYSKrystal Biotech, Inc.COM25,000$3.10M0.6%−32,500−56.5%ReducedHistory
BBIOBridgeBio Pharma, Inc.COM80,000$3.23M0.6%+50,000+166.7%AddedHistory
RLAYRelay Therapeutics, Inc.COM300,000$3.30M0.7%+300,000NewHistory
Coherus Biosciences Inc19249HAB9NOTE 1.500% 4/1–$3.40M0.7%–New–
Omeros Corp682143AG7NOTE 5.250% 2/1–$3.60M0.7%–New–
SWTXSpringWorks Therapeutics, Inc.COM100,000$3.65M0.7%+58,419+140.5%AddedHistory
AXSMAxsome Therapeutics, Inc.COM50,000$3.98M0.8%+50,000NewHistory
AZNAstraZeneca PLCSPONSORED ADR60,000$4.04M0.8%00.0%UnchangedHistory
DVAXDynavax Technologies CorpCOM NEW300,000$4.19M0.8%+100,000+50.0%AddedHistory
MLTXMoonLake ImmunotherapeuticsCLASS A ORD70,988$4.29M0.9%+20,988+42.0%AddedHistory
APLSApellis Pharmaceuticals, Inc.COM75,000$4.49M0.9%+35,000+87.5%AddedHistory
CMPSCOMPASS Pathways plcSPONSORED ADS550,000$4.81M1.0%+550,000NewHistory
SVRASavara IncCOM1,150,000$5.41M1.1%00.0%UnchangedHistory
VKTXViking Therapeutics, Inc.COM300,000$5.58M1.1%00.0%UnchangedHistory
ROIVRoivant Sciences Ltd.SHS500,000$5.62M1.1%+350,000+233.3%AddedHistory
MRTXMirati Therapeutics, Inc.COM100,049$5.88M1.2%+39,623+65.6%AddedHistory
ESTAEstablishment Labs Holdings Inc.COM228,277$5.91M1.2%−10,831−4.5%ReducedHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS795,729$6.33M1.3%−222,362−21.8%ReducedHistory
NRIXNurix Therapeutics, Inc.COM690,112$7.12M1.4%+440,112+176.0%AddedHistory
INZYInozyme Pharma, Inc.COM1,885,802$8.03M1.6%+505,950+36.7%AddedHistory
ALKSAlkermes plc.SHS356,384$9.89M2.0%+256,384+256.4%AddedHistory
AUTLAutolus Therapeutics plcSPON ADS1,550,408$9.98M2.0%−442,058−22.2%ReducedHistory
SYRESpyre Therapeutics, Inc.COM NEW517,554$11.1M2.2%+275,257+113.6%AddedHistory
VRNAVerona Pharma plcSPONSORED ADS563,824$11.2M2.2%+195,495+53.1%AddedHistory
ATXSAstria Therapeutics, Inc.COM1,466,465$11.3M2.2%+466,165+46.6%AddedHistory
NUVLNuvalent, Inc.COM175,000$12.9M2.6%+125,000+250.0%AddedHistory
CYTKCytokinetics IncCOM NEW160,000$13.4M2.7%−70,366−30.5%ReducedHistory
IMVTImmunovant, Inc.COM345,000$14.5M2.9%+45,000+15.0%AddedHistory
APGEApogee Therapeutics, Inc.COM537,093$15.0M3.0%−508,017−48.6%ReducedHistory
CLDXCelldex Therapeutics, Inc.COM NEW400,000$15.9M3.2%+250,000+166.7%AddedHistory
CRNXCrinetics Pharmaceuticals, Inc.COM447,095$15.9M3.2%−2,905−0.6%ReducedHistory
LIANYLianBioSPONSORED ADS3,779,694$16.9M3.4%+3,107,337+462.2%AddedHistory
ACLXArcellx, Inc.COMMON STOCK340,000$18.9M3.8%−60,000−15.0%ReducedHistory
TEVATeva Pharmaceutical Industries LtdSPONSORED ADS1,900,000$19.8M4.0%−100,000−5.0%ReducedHistory
BridgeBio Pharma, Inc.10806XAB8NOTE 2.500% 3/1–$20.6M4.1%–––
XENEXenon Pharmaceuticals Inc.COM460,000$21.2M4.2%+159,562+53.1%AddedHistory
MDGLMadrigal Pharmaceuticals, Inc.COM100,000$23.1M4.6%+15,000+17.6%AddedHistory
CBAYCymaBay Therapeutics, Inc.COM1,090,441$25.8M5.1%−38,935−3.4%ReducedHistory
CERECerevel Therapeutics Holdings, Inc.COM750,000$31.8M6.3%+64,939+9.5%AddedHistory
IMGNImmunoGen, Inc.COM1,404,608$41.6M8.3%+1,404,608NewHistory

Options (9)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q4 2023
SecurityClassPutsCalls
TEVATeva Pharmaceutical Industries LtdSPONSORED ADS–$14.6M
EYPTEyePoint, Inc.COM NEW$7.40M–
ESTAEstablishment Labs Holdings Inc.COM–$5.83M
ALNYAlnylam Pharmaceuticals, Inc.COM–$5.74M
GPCRStructure Therapeutics Inc.SPONSORED ADS–$4.08M
CRNXCrinetics Pharmaceuticals, Inc.COM$3.36M–
FLNAFilana Therapeutics, Inc.COM–$2.72M
APLSApellis Pharmaceuticals, Inc.COM–$1.50M
ALKSAlkermes plc.SHS$749.0K–

Sold out since Q3 2023 (12)

Positions held at the end of Q3 2023 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q3 2023
SecurityClassShares in Q3 2023Value in Q3 2023% of portfolio in Q3 2023History
PRTAProthena Corp Public Ltd CoSHS79,214$3.82M1.2%History
SGENSeagen Inc.COM10,000$2.12M0.7%History
LNTHLantheus Holdings, Inc.Stock30,000$2.08M0.7%History
INSPInspire Medical Systems, Inc.COM6,293$1.25M0.4%History
TRMLTourmaline Bio, Inc.COM400,000$1.12M0.4%History
THRXTheseus Pharmaceuticals, Inc.COM400,726$1.08M0.4%History
MISTMilestone Pharmaceuticals Inc.COM335,068$1.04M0.3%History
TVTXTravere Therapeutics, Inc.COM100,000$894.0K0.3%History
PODDInsulet CorpStock5,000$797.5K0.3%History
BCABBioAtla, Inc.COM180,000$306.0K0.1%History
ALDXAldeyra Therapeutics, Inc.COM44,348$296.2K0.1%History
NLS Pharmaceutics LtdH57830103SHS200,455$140.3K<0.1%–